Related Experiment Video

Updated: Jun 16, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-Eluting stenting

Seung-Whan Lee1, Seong-Wook Park, Sung-Cheol Yun

  • 1Department of Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.

American Heart Journal
|February 16, 2010
PubMed

Insights

Triple antiplatelet therapy with cilostazol significantly reduced stent thrombosis and myocardial infarction (MI) after drug-eluting stent (DES) implantation. This approach did not increase bleeding risk, suggesting improved cardiac event prevention.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Pharmacology

Background:

  • Cilostazol is known to reduce restenosis and repeat interventions post-drug-eluting stent (DES) implantation.
  • Limited data exists on cilostazol's impact on cardiac events following DES procedures.
  • This study investigates the long-term efficacy and safety of cilostazol in patients after successful DES implantation.

Purpose of the Study:

  • To assess the long-term efficacy and safety of triple antiplatelet therapy (aspirin, clopidogrel, and cilostazol) versus dual antiplatelet therapy (aspirin and clopidogrel) after successful DES implantation.
  • To compare the incidence of major adverse cardiac events, including death, myocardial infarction (MI), and stent thrombosis, between the two treatment groups.

Main Methods:

  • A cohort of 3,099 patients undergoing successful DES implantation was analyzed.
  • Patients received either triple antiplatelet therapy (n=1,443) or dual antiplatelet therapy (n=1,656).
  • Outcomes were compared at 12 months using inverse probability of treatment weighting (IPTW) and propensity score matching.

Main Results:

  • IPTW analysis showed no significant difference in 12-month mortality between groups.
  • Triple therapy significantly reduced 12-month rates of myocardial infarction (MI) and stent thrombosis compared to dual therapy.
  • No significant difference in major bleeding events was observed between the triple and dual therapy groups.

Conclusions:

  • Triple antiplatelet therapy with cilostazol significantly lowers the risk of stent thrombosis and MI after DES implantation without increasing bleeding risk.
  • Extended duration of triple therapy post-DES implantation is associated with reduced risks of stent thrombosis and MI.
Abstract

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...